AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
Sponsor: Notable Labs
A observational or N/A phase clinical study on Acute Myeloid Leukemia and Myelodysplastic Syndromes, this trial is ongoing. The trial is conducted by Notable Labs and has accumulated 15 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
15 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting
-
Sep 2025 — Mar 2026 [monthly]
Active Not Recruiting
-
Mar 2025 — Sep 2025 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Mar 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
▶ Show 10 earlier versions
-
Sep 2023 — Jul 2024 [monthly]
Recruiting
-
Sep 2022 — Sep 2023 [monthly]
Recruiting
-
Apr 2022 — Sep 2022 [monthly]
Recruiting
-
Jun 2021 — Apr 2022 [monthly]
Recruiting
-
Apr 2021 — Jun 2021 [monthly]
Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Recruiting
-
Oct 2020 — Dec 2020 [monthly]
Recruiting
-
Apr 2020 — Oct 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Mar 2020 — Apr 2020 [monthly]
Not Yet Recruiting
First recorded
Jan 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Notable Labs
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .